Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) April 28, 2014

Differentiating Plovamer Acetate and Glatiramer Acetate: Efficacy and Mechanism of Action in a Preclinical Model of Multiple Sclerosis (P1.187)

Anneli Savinainen, Kenneth Crook, Timothy Crandall, Michelle Seng, Ursula Boschert, Tammy Dellovade
First published April 9, 2014,
Anneli Savinainen
1EMD Serono Research & Development Institute Billerica MA United States
2EMD Serono Research & Development Institute Billerica MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Crook
1EMD Serono Research & Development Institute Billerica MA United States
2EMD Serono Research & Development Institute Billerica MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Crandall
1EMD Serono Research & Development Institute Billerica MA United States
2EMD Serono Research & Development Institute Billerica MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Seng
1EMD Serono Research & Development Institute Billerica MA United States
2EMD Serono Research & Development Institute Billerica MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ursula Boschert
1EMD Serono Research & Development Institute Billerica MA United States
2EMD Serono Research & Development Institute Billerica MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tammy Dellovade
1EMD Serono Research & Development Institute Billerica MA United States
2EMD Serono Research & Development Institute Billerica MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Differentiating Plovamer Acetate and Glatiramer Acetate: Efficacy and Mechanism of Action in a Preclinical Model of Multiple Sclerosis (P1.187)
Anneli Savinainen, Kenneth Crook, Timothy Crandall, Michelle Seng, Ursula Boschert, Tammy Dellovade
Neurology Apr 2014, 82 (10 Supplement) P1.187;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: To compare the response to plovamer acetate (PA) and glatiramer acetate (GA) and investigate the mechanism of action (MOA) in a preclinical model of relapsing-remitting multiple sclerosis (RRMS). BACKGROUND: PA is a copolymer mixture of four amino acids of defined ratio, rationally designed to have improved efficacy over GA. PA competitively binds to MHC II with higher affinity than GA and drives a T-helper cell (Th)2-like response. PA is undergoing Phase II testing for RRMS. METHODS: Experimental autoimmune encephalomyelitis (EAE) was induced in SJL/J mice. PA, GA or vehicle were administered subcutaneously either daily or three times/week, or were co-administered with PLP at EAE induction. Disease severity was measured using a standard 0-5 clinical score (CS) scale. Blood and plasma were collected weekly for hematology and cytokine production measurements, respectively. Mouse splenocytes were cultured and re-stimulated to assess proliferation and cytokine production. RESULTS: Disease onset was delayed significantly vs. vehicle with daily PA (5 days; p<0.001), daily GA (2 days; p<0.01), PA 3x/week (6 days; p<0.001), but not GA 3x/week. In addition, PA dose-dependently decreased EAE severity when co-administered at disease induction: 10 or 30 mg/kg completely abolished disease and 3 mg/kg resulted in a 60% decrease in EAE severity. In contrast, co-administration of 3 or 10 mg/kg of GA was not efficacious; 30 mg/kg resulted in a similar decrease in CS as seen with 3 mg/kg PA, suggesting that PA was 10x more potent than GA in this preclinical model. Additional results supported previous findings that PA induces a Th2 shift. CONCLUSIONS: When compared with GA, PA more potently delays disease onset and reduces disease severity, as demonstrated in a preclinical model of RRMS. Continuing studies will provide further details on MOA. Study Supported by: Merck Serono SA Geneva, Switzerland, a subsidiary of Merck KGaA, Darmstadt, Germany.

Disclosure: Dr. Savinainen has received personal compensation for activities with EMD Serono. Dr. Crook has received personal compensation for activities with EMD Serono as an employee. Dr. Crandall has received personal compensation for activities with EMD Serono as an employee. Dr. Seng has received personal compensation for activities with EMD Serono as an employee. Dr. Boschert has received personal compensation for activities with EMD Serono as an employee. Dr. Dellovade has received personal compensation for activities with EMD Serono as an employee.

Monday, April 28 2014, 3:00 pm-6:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (9)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise